

# SEQUENCE LISTING

<110> Ullrich, Axel  
Bange, Johannes  
Knyazev, Pjotr

<120> Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer

<130> 205884

<140> US 09/600,826

<141> 2000-09-07

<150> PCT/EP99/00405

<151> 1999-01-22

<150> DE 198 02 377.4

<151> 1998-01-22

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 25

<212> PRT

<213> Homo sapiens

<220>

<221> DOMAIN

<222> (1)..(25)

<223> amino acid sequence of  
FGFR-4 (mutant) between positions 366-390

<400> 1

Arg	Tyr	Thr	Asp	Ile	Ile	Leu	Tyr	Ala	Ser	Gly	Ser	Leu	Ala	Leu	Ala
1				5			10						15		

Val	Leu	Leu	Leu	Leu	Ala	Arg	Leu	Tyr
			20				25	

<210> 2

<211> 25

<212> PRT

<213> Homo sapiens

<220>

<221> DOMAIN

<222> (1)..(25)

<223> amino acid sequence of  
FGFR-4 (wild-type) between positions 366-390

<400> 2

Arg	Tyr	Thr	Asp	Ile	Ile	Leu	Tyr	Ala	Ser	Gly	Ser	Leu	Ala	Leu	Ala
1				5			10						15		

Val Leu Leu Leu Leu Ala Gly Leu Tyr  
20 25

<210> 3  
<211> 29  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer for the amplification of FGFR-4 (wild-type and mutant)

<400> 3  
gctcagaggg cgggcggggg tgccggccg 29

<210> 4  
<211> 33  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer for the amplification of FGFR-4 (wild-type and mutant)

<400> 4  
ccgctcgagt gcctgcacag ccttgagcct tgc 33

<210> 5  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer for the amplification of the transmembrane domain of FGFR-4  
(wild-type and mutant)

<400> 5  
gaccgcagca gcgcccagg ccag 24

<210> 6  
<211> 23  
<212> DNA  
<213> artificial sequence

<220>  
<223> PCR primer for the amplification of the transmembrane domain of FGFR-4  
(wild-type and mutant)

<400> 6  
agagggaaga gggagagctt ctg 23

<210> 7  
<211> 28  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer for sequencing of the transmembrane domain of FGFR-4

(wild-type and mutant)

<400> 7

gggaattcga ccgcagcagc gcccgagg

28

<210> 8

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> primer for sequencing of the transmembrane domain of FGFR-4  
(wild-type and mutant)

<400> 8

gctctagaag aggggaagagg gagag

25

## SEQUENCE PROTOCOL

<110> Max-Planck Society for the Promotion of Science e.V., Berlin  
 <120> Use of inhibitors for the treatment of RTK hyperfunction-induced disorders, particularly cancer.

<130> P29374-03166

<140>

<141>

<160> 2

<170> PatentIn Vers. 2.0

<210> 1

<211> 25

<212> PRT

<213> Artificial sequence

<400> 1

Arg	Tyr	Thr	Asp	Ile	Ile	Leu	Tyr	Ala	Ser	Gly	Ser	Leu	Ala	Leu	Ala
1				5			10					15			
Val	Leu	Leu	Leu	Leu	Ala	Arg	Leu	Tyr							
			20				25								

<210> 2

<211> 25

<212> PRT

<213> Artificial sequence

<400> 2

Arg	Tyr	Thr	Asp	Ile	Ile	Leu	Tyr	Ala	Ser	Gly	Ser	Leu	Ala	Leu	Ala
1				5			10					15			
Val	Leu	Leu	Leu	Leu	Ala	Gly	Leu	Tyr							
			20				25								